# A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

> **NCT04541810** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 2369 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Atopic Dermatitis (AD)
- Ankylosing Spondylitis (AS)
- Psoriatic Arthritis (PsA)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04541810
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 2369 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541810, "A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04541810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*